Destiny Wealth Partners LLC raised its holdings in shares of Sanofi (NASDAQ:SNY – Get Rating) by 162.0% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 676 shares of the company's stock after purchasing an additional 418 shares during the period. Destiny Wealth Partners LLC's holdings in Sanofi were worth $34,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in SNY. GHP Investment Advisors Inc. acquired a new position in shares of Sanofi in the 1st quarter valued at $26,000. Fairfield Bush & CO. acquired a new position in shares of Sanofi in the 1st quarter valued at $26,000. Pinnacle Bancorp Inc. increased its position in shares of Sanofi by 49.0% in the 1st quarter. Pinnacle Bancorp Inc. now owns 587 shares of the company's stock valued at $30,000 after acquiring an additional 193 shares during the period. Ahrens Investment Partners LLC acquired a new position in shares of Sanofi in the 1st quarter valued at $31,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Sanofi in the 1st quarter valued at $32,000. 10.33% of the stock is owned by institutional investors and hedge funds.

Sanofi Stock Down 1.9 %

SNY stock opened at $38.40 on Monday. The company has a quick ratio of 0.34, a current ratio of 1.29 and a debt-to-equity ratio of 0.22. Sanofi has a fifty-two week low of $38.01 and a fifty-two week high of $58.10. The firm's 50-day simple moving average is $43.59 and its 200 day simple moving average is $48.48. The stock has a market cap of $97.34 billion, a PE ratio of 12.76, a price-to-earnings-growth ratio of 0.97 and a beta of 0.53.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Credit Suisse Group upped their target price on Sanofi from €105.00 ($107.14) to €110.00 ($112.24) and gave the company an "outperform" rating in a research report on Friday, July 22nd. StockNews.com raised Sanofi from a "buy" rating to a "strong-buy" rating in a research report on Sunday, August 14th. Cheuvreux downgraded Sanofi from a "buy" rating to a "hold" rating in a research report on Wednesday, August 24th. JPMorgan Chase & Co. increased their price target on Sanofi from €105.00 ($107.14) to €115.00 ($117.35) in a research report on Monday, August 1st. Finally, UBS Group downgraded Sanofi from a "buy" rating to a "neutral" rating in a research report on Tuesday, August 9th. Four research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Sanofi has a consensus rating of "Moderate Buy" and a consensus price target of $105.38.

About Sanofi

(Get Rating)

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.

Further Reading

• Get a free copy of the StockNews.com research report on Sanofi (SNY)
• Can Caterpillar Claw Higher in a Falling Market?
• Is Dave & Buster's Immune to High Inflation and Lower Spending?
• Should These 3 Top-Performing Mid-Caps Be On Your Watchlist?
• Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
• MarketBeat: Week in Review 9/19 – 9/23

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY – Get Rating).

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.